Date: 2015-08-05
Type of information: Private placement
Company: Amag Pharmaceuticals (USA - MA)
Investors:
Amount: $231 Million (€ 212.1 million)
Funding type: private placement
Planned used: Amag Pharmaceuticals intends to use the net proceeds from this offering for the expansion and diversification of its product portfolio through the in-license or purchase of additional pharmaceutical products or companies, such as Cord Blood Registry (CBR), to refinance certain existing indebtedness, to pay various fees and expenses incurred in connection with the CBR acquisition and related financing transactions, as well as for general corporate purposes.
Others: * On August 5, 2015, Amag Pharmaceuticals announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 472,500 shares of common stock at the public offering price of $63.75 per share. The exercise of the underwriters\' option brought the total number of shares of common stock sold by AMAG to 3,622,500 and increased the total gross proceeds raised in the offering to approximately $230.9 million, before deducting the underwriting discounts, commissions and estimated expenses. * On July 30, 2015, Amag Pharmaceuticals announced that it has priced its previously announced underwritten public offering of common stock consisting of 3,150,000 shares at a public offering price of $63.75 per share. Gross proceeds to AMAG from this offering are expected to be approximately $201 million. Amag has granted the underwriters a 30-day option to purchase up to an additional 472,500 shares of common stock offered in the public offering. All of the shares in the offering will be sold by Amag. The offering is expected to close on August 5, 2015, subject to customary closing conditions. * On July 29, 2015, Amag Pharmaceuticals announced that it has commenced an underwritten public offering of approximately $200 million of its common stock. Amag intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering. All of the shares in the offering will be sold by Amag. Jefferies LLC and Barclays Capital Inc. are acting as joint book-running managers for the offering. The offering is subject to market and other conditions and there can be no assurances as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Therapeutic area:
